Takeover interest in Germany's chemicals sector is intensifying after BASF disclosed a potential acquisition proposal for Evonik. Evonik rejects an offer valued at about 22.15 euros per share as inadequate, pointing to an early impasse in a possible sector deal.
Highlights
- Evonik rejects BASF's takeover offer at approximately 22.15 euros per share, citing the bid as too low, per sources.
- BASF confirms proposing an acquisition of Evonik but declines to specify offer details or respond to Evonik's public silence.
- The rejected bid underscores valuation gaps and indicates BASF must improve terms for any renewed talks, impacting German chemical sector consolidation prospects.
Offer terms and company responses
As first reported by Reuters, citing the Financial Times, Evonik rejects a takeover offer of about 22.15 euros per share from larger rival BASF because it considers the proposal too low, according to two people familiar with the matter.BASF says on Friday that it has proposed a potential acquisition of Evonik, but on Monday declines to comment on the size of the offer. Evonik also declines to comment publicly on the approach.
Implications for the German chemicals sector
The rejected proposal signals valuation tensions in any prospective consolidation move among major German chemicals groups. It also suggests that any further negotiations would likely require BASF to improve terms if it wants to advance discussions.The approach keeps investor focus on strategic options in Europe's chemicals industry, where scale, portfolio reshaping and market conditions remain important factors in dealmaking.
BioNTech’s decision to shut manufacturing sites in Germany and Singapore highlighted how companies are reshaping capacity as post-pandemic demand fades. Our earlier article noted that the closures followed an unsuccessful attempt to find buyers for the facilities and were linked to shifting COVID-19 vaccine production to partner Pfizer, alongside agreed measures to support affected employees.